Antiretroviral Medications, Adult Care, and Treatment
Entry inhibitors: ARV medications in this class of ARVs effectively interfere with the receptor-mediated entry of the HIV virus into a cell. One subclass of entry inhibitors is the CCR5 antagonists; and the one medication approved for use currently in this subclass is maraviroc, with viroc standing for virus occupying. A new medication in this class, cenicriviroc, is currently in preclinical studies and may be available soon.
Fusion inhibitors: ARV...
- Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, the Antiretroviral Research for Watoto (ARROW) Trial Team. A randomized trial of stopping or continuing co-trimoxazole in HIV-infected children. N Engl J Med. 2014;370:41–53.CrossRefPubMedPubMedCentralGoogle Scholar
- Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue co-trimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54:1204–11.CrossRefPubMedGoogle Scholar
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21767103.CrossRefPubMedPubMedCentralGoogle Scholar
- Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach – Second edition; released/published http://www.who.int/hiv/pub/arv/arv-2016/en/. Updated/released June 2016.
- Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532–8. Available at http://www.ncbi.nlm.nih.gov/pubmed/20415574.CrossRefPubMedGoogle Scholar
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) and last updated July 14th, 2016. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 Aug 2017.
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 22 Aug 2017; pp 160–170.
- Polyak CS, Yuhas K, Singa B, Khaemba M, Watson J, Richardson B et al. CTX prophylaxis discontinuation among ART treated adults: a randomized non-inferiority trial. In: Twenty-first conference on retroviruses and opportunistic infections (CROI), Boston, 3–6 Mar 2014 [Abstract 98]. http://www.croiconference.org/sites/default/files/abstracts/98.pdf. Accessed 11 Nov 2015.
- UNAIDS fact sheet (released July 2017). Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.
- Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. Available at http://www.ncbi.nlm.nih.gov/pubmed/19440326.CrossRefPubMedPubMedCentralGoogle Scholar